Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Safety, Tolerability and Pharmacokinetics 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol in Healthy Subjects

Trial Profile

A Randomized, Safety, Tolerability and Pharmacokinetics 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosfomycin (Primary) ; Fosfomycin tromethamine
  • Indications Pseudomonal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Oct 2017 Outcomes of population pharmacokinetic analysis (refinement) of ZTI-01 using pooled data from healthy subjects (NCT02178254) and patients (NCT02753946) with complicated urinary tract infections, presented at the IDWeek 2017.
    • 05 Jun 2017 According to the Zavante Therapeutics media release, results from the study were be presented at the ASM Microbe 2017.
    • 17 May 2017 According to the Zavante Therapeutics media release, data from the study will be presented at the ASM Microbe 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top